1. Home
  2. PHAR vs LYTS Comparison

PHAR vs LYTS Comparison

Compare PHAR & LYTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHAR
  • LYTS
  • Stock Information
  • Founded
  • PHAR 1988
  • LYTS 1976
  • Country
  • PHAR Netherlands
  • LYTS United States
  • Employees
  • PHAR N/A
  • LYTS N/A
  • Industry
  • PHAR Biotechnology: Pharmaceutical Preparations
  • LYTS Building Products
  • Sector
  • PHAR Health Care
  • LYTS Consumer Discretionary
  • Exchange
  • PHAR Nasdaq
  • LYTS Nasdaq
  • Market Cap
  • PHAR 718.1M
  • LYTS 518.5M
  • IPO Year
  • PHAR N/A
  • LYTS N/A
  • Fundamental
  • Price
  • PHAR $10.27
  • LYTS $17.85
  • Analyst Decision
  • PHAR Strong Buy
  • LYTS Strong Buy
  • Analyst Count
  • PHAR 3
  • LYTS 2
  • Target Price
  • PHAR $30.00
  • LYTS $26.00
  • AVG Volume (30 Days)
  • PHAR 4.3K
  • LYTS 105.7K
  • Earning Date
  • PHAR 07-31-2025
  • LYTS 08-14-2025
  • Dividend Yield
  • PHAR N/A
  • LYTS 1.12%
  • EPS Growth
  • PHAR N/A
  • LYTS N/A
  • EPS
  • PHAR N/A
  • LYTS 0.72
  • Revenue
  • PHAR $320,708,000.00
  • LYTS $547,316,000.00
  • Revenue This Year
  • PHAR $13.31
  • LYTS $21.02
  • Revenue Next Year
  • PHAR $7.68
  • LYTS $7.32
  • P/E Ratio
  • PHAR N/A
  • LYTS $24.79
  • Revenue Growth
  • PHAR 24.13
  • LYTS 17.89
  • 52 Week Low
  • PHAR $6.65
  • LYTS $13.63
  • 52 Week High
  • PHAR $12.61
  • LYTS $25.50
  • Technical
  • Relative Strength Index (RSI)
  • PHAR 48.21
  • LYTS 68.63
  • Support Level
  • PHAR $10.46
  • LYTS $16.92
  • Resistance Level
  • PHAR $11.49
  • LYTS $17.35
  • Average True Range (ATR)
  • PHAR 0.37
  • LYTS 0.36
  • MACD
  • PHAR -0.12
  • LYTS 0.11
  • Stochastic Oscillator
  • PHAR 27.62
  • LYTS 100.00

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

About LYTS LSI Industries Inc.

LSI Industries Inc provides corporate visual image solutions to the petroleum and convenience store industry. The company's operating segments include Lighting and Display Solutions. It generates maximum revenue from the Lighting segment. Lighting Segment manufactures and markets outdoor and indoor lighting and lighting controls for the commercial, industrial, and multi-site retail markets including the petroleum/convenience store, quick-service, and automotive markets. The Display Solutions Segment manufactures, sells and installs exterior and interior visual image and display elements, including printed graphics, structural graphics, digital signage, menu board systems, display fixtures, refrigerated displays and custom display elements.

Share on Social Networks: